NM_130839.5(UBE3A):c.2423G>A (p.Gly808Asp)

Base Editing (ABE8e) via AAV9 delivery is a rationale-driven therapeutic strategy for Angelman Syndrome targeting the UBE3A c.2423G>A (p.Gly808Asp) variant (Pathogenic, missense variant, non-coding transcript variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Correct UBE3A nonsense mutation at chr15:25,433,037 to restore full-length protein expression and ubiquitin ligase activity in neurons. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: UBE3A NM_130839.5(UBE3A):c.2423G>A (p.Gly808Asp) is classified as Pathogenic (ClinVar variation ID 1067820). Molecular consequence: missense variant, non-coding transcript variant. Protein change: G371D, G391D, G733D, G736D, G749D, G756D, G788D, G808D, G811D. 2. Epidemiology: 1 in 12,000-20,000 live births (~500,000 globally), no gender preference, affects males and females equally 3. Standard of care: Symptomatic management only (antiepileptics, physical/occupational/speech therapy, sleep management), no disease-modifying treatments approved 4. Pipeline: Phase 3: ION582 (ASO), GTX-102 (ASO); Preclinical/IND-enabling: AAV gene therapy, CRISPR approaches 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting UBE3A c.2423G>A (p.Gly808Asp) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 4. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.